Overview

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aileron Therapeutics
Aileron Therapeutics, Inc.